Trial · NCT02132832

Buspirone, Stress, and Attentional Bias to Marijuana Cues

NCT02132832, Phase 2, Completed, The University of Texas Health Science Center, Houston; results first posted 2017-04-07

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Buspirone, Stress, and Attentional Bias to Marijuana Cues. Trials, record NCT02132832. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02132832

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Buspirone, Stress, and Attentional Bias to Marijuana Cues
NCT number: NCT02132832
Status: Completed
Phases: Phase 2
Enrollment: 45 participants, actual
Lead sponsor: The University of Texas Health Science Center, Houston
Conditions: Cannabis Use Disorder
Interventions: Buspirone, Placebo
First posted: 2014-05-07
Last updated: 2017-06-02
Results first posted: 2017-04-07
Limitations and caveats: The study intends to evaluate reduction of attentional-bias in non-treatment seekers, and it is not designed or powered to address treatment effects on marijuana use.

Source ClinicalTrials.gov

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements	week 1	Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: \[(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)\]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
Primary	Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements	week 2	Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: \[(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)\]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
Primary	Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements	week 3	Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: \[(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)\]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
Primary	Stress as Assessed by the Perceived Stress Scale	week 1	The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.
Primary	Stress as Assessed by the Perceived Stress Scale	week 2	The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.
Primary	Stress as Assessed by the Perceived Stress Scale	week 3	The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.
Primary	Anxiety as Assessed by the Zung Self-Rated Anxiety Scale	week 1	The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: * 20-44 Normal Range * 45-59 Mild to Moderate Anxiety Levels * 60-74 Marked to Severe Anxiety Levels * 75-80 Extreme Anxiety Levels
Primary	Anxiety as Assessed by the Zung Self-Rated Anxiety Scale	week 2	The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: * 20-44 Normal Range * 45-59 Mild to Moderate Anxiety Levels * 60-74 Marked to Severe Anxiety Levels * 75-80 Extreme Anxiety Levels
Primary	Anxiety as Assessed by the Zung Self-Rated Anxiety Scale	week 3	The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: * 20-44 Normal Range * 45-59 Mild to Moderate Anxiety Levels * 60-74 Marked to Severe Anxiety Levels * 75-80 Extreme Anxiety Levels
Primary	Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)	week 1	With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."

1 to 10 of 12Source ClinicalTrials.gov

See all 12 registered outcomes

Outcomes12

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements	week 1	ratio of errors (see OM description)	MEAN
PRIMARY	Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements	week 2	ratio of errors (see OM description)	MEAN
PRIMARY	Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements	week 3	ratio of errors (see OM description)	MEAN
PRIMARY	Stress as Assessed by the Perceived Stress Scale	week 1	units on a scale	MEAN
PRIMARY	Stress as Assessed by the Perceived Stress Scale	week 2	units on a scale	MEAN
PRIMARY	Stress as Assessed by the Perceived Stress Scale	week 3	units on a scale	MEAN
PRIMARY	Anxiety as Assessed by the Zung Self-Rated Anxiety Scale	week 1	units on a scale	MEAN
PRIMARY	Anxiety as Assessed by the Zung Self-Rated Anxiety Scale	week 2	units on a scale	MEAN
PRIMARY	Anxiety as Assessed by the Zung Self-Rated Anxiety Scale	week 3	units on a scale	MEAN
PRIMARY	Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)	week 1	units on a scale	MEAN

1 to 10 of 12Source ClinicalTrials.gov

See all 12 outcomes

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements	Buspirone	0.5795019	Standard Deviation 0.1609511	ratio of errors (see OM description)
Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements	Placebo	0.5539831	Standard Deviation 0.1442601	ratio of errors (see OM description)
Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements	Buspirone	0.5517691	Standard Deviation 0.1319968	ratio of errors (see OM description)
Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements	Placebo	0.4979594	Standard Deviation 0.1486691	ratio of errors (see OM description)
Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements	Buspirone	0.5503957	Standard Deviation 0.1133407	ratio of errors (see OM description)
Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements	Placebo	0.531073	Standard Deviation 0.1991689	ratio of errors (see OM description)
Stress as Assessed by the Perceived Stress Scale	Buspirone	15.05556	Standard Deviation 5.885898	units on a scale
Stress as Assessed by the Perceived Stress Scale	Placebo	18.57895	Standard Deviation 6.551639	units on a scale
Stress as Assessed by the Perceived Stress Scale	Buspirone	13.88889	Standard Deviation 6.434182	units on a scale
Stress as Assessed by the Perceived Stress Scale	Placebo	16.42105	Standard Deviation 5.708822	units on a scale

1 to 10 of 24Source ClinicalTrials.gov

See all 24 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Buspirone	19
Overall Study	STARTED	Placebo	23
Overall Study	COMPLETED	Buspirone	16
Overall Study	COMPLETED	Placebo	16
Overall Study	NOT COMPLETED	Buspirone	3
Overall Study	NOT COMPLETED	Placebo	7

Source ClinicalTrials.gov

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	light-headed, dizziness	Nervous system disorders	Buspirone	1	19	1
other	light-headed, dizziness	Nervous system disorders	Placebo	0	23	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Buspirone
Total, all-cause mortality	Placebo
Total, other adverse events	Buspirone	1	19
Total, other adverse events	Placebo	0	23
Total, serious adverse events	Buspirone	0	19
Total, serious adverse events	Placebo	0	23

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R21DA034825	Buspirone, Stress, and Attentional Bias to Marijuana Cues	LANE, SCOTT D	UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON	NATIONAL INSTITUTE ON DRUG ABUSE	2013 to 2014

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Buspirone vs Placebo: serious adverse events

Source Trial comparisons

Tests1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as
Antisaccade Task	Primary outcome

Source ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02132832

GET https://conductscience.org/api/trials/v1/NCT02132832/results?page=2

API reference For AI assistants